作者: Navin Pinto , Eric R Gamazon , Nirav Antao , Jamie Myers , Amy L Stark
DOI: 10.1038/CLPT.2014.37
关键词:
摘要: High-risk neuroblastoma is an aggressive malignancy, with high rates of treatment failure. We evaluated genetic variants associated in vitro sensitivity to two derivatives cyclophosphamide for association clinical response a separate replication cohort patients (n = 2,709). To determine sensitivity, lymphoblastoid cell lines (LCLs) were exposed increasing concentrations 4-hydroperoxycyclophosphamide (4HC; n 422) and phosphoramide mustard (PM; 428). Genome-wide studies performed identify single-nucleotide polymorphisms (SNPs) 4HC PM. SNPs consistently LCL analyzed associations event-free survival (EFS) patients. Two linked SNPs, rs9908694 rs1453560, found be (i) PM LCLs across populations (ii) EFS all (P 0.01) within the high-risk subset 0.05). Our study highlights value cell-based models candidate that may predict cancer. Clinical Pharmacology & Therapeutics (2014); 95 6, 644–652. doi:10.1038/clpt.2014.37